Pacific Biosciences of California (PACB) to Post Quarterly Earnings on Monday

Pacific Biosciences of California (NASDAQ:PACB) is expected to release its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect Pacific Biosciences of California to post earnings of ($0.1280) per share and revenue of $42.9030 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Pacific Biosciences of California (NASDAQ:PACB) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. The business had revenue of $37.18 million for the quarter, compared to analyst estimates of $39.94 million. Pacific Biosciences of California had a negative net margin of 80.35% and a negative return on equity of 571.06%. On average, analysts expect Pacific Biosciences of California to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Pacific Biosciences of California Price Performance

Shares of Pacific Biosciences of California stock opened at $1.36 on Monday. The stock’s 50 day simple moving average is $1.44 and its 200-day simple moving average is $1.60. The stock has a market cap of $422.42 million, a P/E ratio of -3.16 and a beta of 2.29. Pacific Biosciences of California has a 1-year low of $1.09 and a 1-year high of $2.73.

Institutional Trading of Pacific Biosciences of California

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Intech Investment Management LLC raised its position in shares of Pacific Biosciences of California by 5.2% during the 3rd quarter. Intech Investment Management LLC now owns 132,368 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 6,564 shares during the period. Mercer Global Advisors Inc. ADV grew its position in Pacific Biosciences of California by 47.9% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 20,663 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 6,695 shares during the period. Cetera Investment Advisers increased its stake in Pacific Biosciences of California by 10.1% during the second quarter. Cetera Investment Advisers now owns 104,725 shares of the biotechnology company’s stock worth $130,000 after acquiring an additional 9,617 shares during the last quarter. Raymond James Financial Inc. increased its stake in Pacific Biosciences of California by 6.5% during the third quarter. Raymond James Financial Inc. now owns 161,865 shares of the biotechnology company’s stock worth $207,000 after acquiring an additional 9,896 shares during the last quarter. Finally, Deutsche Bank AG raised its position in Pacific Biosciences of California by 4.8% in the fourth quarter. Deutsche Bank AG now owns 218,981 shares of the biotechnology company’s stock valued at $409,000 after purchasing an additional 10,107 shares during the period.

Analysts Set New Price Targets

PACB has been the topic of a number of analyst reports. Zacks Research downgraded Pacific Biosciences of California from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Pacific Biosciences of California in a report on Friday, July 17th. Finally, Barclays raised their target price on Pacific Biosciences of California from $1.00 to $1.50 and gave the stock an “underweight” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $1.83.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.